No Survival Benefit from Adding Adjuvant Chemotherapy to Endocrine Therapy in Older Women with a Genomic Grade Index High-Risk ER-positive, HER2-negative Breast Cancer By Ogkologos - August 19, 2025 714 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ASTER 70s study Source RELATED ARTICLESMORE FROM AUTHOR Tambotatug Pelitecan Leads to Better Clinical Outcomes than Topotecan Among Patients with Relapsed SCLC After Platinum-based Therapy ESMO Welcomes European Parliament Calls to Strengthen and Protect Europe’s Cancer Workforce No improvement in OS, but more grade 3 or higher AEs with atezolizumab plus SBRT among patients with inoperable early-stage NSCLC MOST POPULAR FDA Approves Nivolumab for Adjuvant Treatment of Urothelial Carcinoma August 24, 2021 Studies Test CAR T-Cell Therapies Designed to Overcome Key Limitations February 8, 2023 3 Things to Reduce Stress During Cancer Treatment: A Patient’s Perspective January 30, 2024 Our COVID-19 Response: How We’re Supporting Frontline Workers At Revolution Foods April 27, 2020 Load more HOT NEWS How Decades of NCI Support Led to Groundbreaking Discoveries: The Story... ESMO Sarcoma & GIST Symposium 2022, 31 January – 2 February 2022 ASCO Annual Meeting: A New Targeted Therapy Combination for Low-Grade Brain... EMA Recommends Extension of Therapeutic Indications for Cabozantinib and Nivolumab
